CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Honor Your StaffCelebrate Lab Week, and honor yourself and your colleagues as a vital part of the la...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...